0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Yttrium 90 Microsphere Selective Internal Radiation Treatment of Hepatic Colorectal Metastases

Timothy J. Price, MBBS, FRACP; Amanda Townsend, MBBS
Arch Surg. 2008;143(3):313-314. doi:10.1001/archsurg.2007.65.
Text Size: A A A
Published online

Extract

We read with interest the review of yttrium 90 microsphere selective internal radiation treatment (SIRT) by Gulec et al.1 The authors discussed the administration technique, benefits, and complications of SIRT. They note the importance of combining SIRT with chemotherapy, in particular 5-fluorouracil (5-FU) as a radiosensitizer, and recommend chemotherapy be given in “close temporal proximity to the radiation.” In conclusion they state that SIRT has a potential role in the multimodality treatment of unresectable colorectal cancer metastases, but further data are required to determine the optimal strategy of multimodality treatment. We have recently reviewed the topic of combining chemotherapy and SIRT and found there is a lack of guidance in the literature on the appropriate timing of chemotherapy administration in relation to SIRT. In the most recent report, SIRT was administered in combination with 5-FU and oxaliplatin.2 There is, however, a theoretical risk of arterial spasm when administering 5-FU at the time of hepatic arterial access for SIRT delivery. While there are no reported arterial events in the current literature, arterial complications related to 5-FU are common. Südhoff et al3 performed high-resolution ultrasonography of the brachial artery in 30 patients receiving 5-FU. Contraction of the brachial artery occurred in 50% of patients, confirming that systemic arterial vasoconstriction beyond the heart is common in patients receiving 5-FU. We believe there is a need to define the timing of 5-FU administration in relation to SIRT in a more standardized fashion, taking into account this potential toxicity, before the role of SIRT in the multimodality treatment of unresectable hepatic colorectal metastases can be defined.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();